Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

WW International (NASDAQ:WW) stock surges with a new partnership to offer Eli Lilly's (LLY) weight-loss therapy Zepbound.

WW International shares are trading higher by 79% during Tuesday's session. The company announced a new partnership with Eli ...

Eli Lilly (LLY) reported first quarter earnings on Thursday, beating Wall Street's expectations on the top and bottom lines, but GLP-1 sales weren't as strong as expected. The company reported ...

Eli Lilly rose Friday after topping Wall Street's first-quarter expectations. Eli Lilly stock bounced back after tumbling Thursday after CVS' Caremark selected Novo Nordisk's Wegovy as its preferred ...